





97. A method according to claim 95 wherein ultrafiltration is performed at a pH between about 9 and 10.
98. A method according to claim 78 wherein the second peptidyl fragment exhibits insulin-like bioactivity in its bioactive conformation.
99. A method according to claim 78 wherein the second peptidyl fragment is capable of being bound by an anti-human-insulin antibody.
100. A method according to claim 78 wherein the second peptidyl fragment is an insulin precursor.
101. A method according to claim 78 wherein the second peptidyl fragment is an insulin precursor of human origin.
102. A method according to claim 78 wherein the second peptidyl fragment comprises SEQ. ID. No. 4.
103. A method according to claim 78 wherein the second peptidyl fragment comprises SEQ. ID. No. 5.
104. A method according to claim 78 wherein the second peptidyl fragment comprises A chain and B chain amino acid sequences of human insulin separated by an amino acid sequence between 1 and 34 residues in length.
105. A method according to claim 78 wherein the second peptidyl fragment comprises at least four cysteine residues which form two cysteine bridges.
106. A method according to claim 78 wherein the second peptidyl fragment comprises at least six cysteine residues which form three cysteine bridges
107. A method according to claim 106 wherein the first peptidyl fragment is capable